Wall Street is positive on BIO-TECHNE Corp (TECH). On average, analysts give BIO-TECHNE Corp a Strong Buy rating. The average price target is $244.25, which means analysts expect the stock to rise by 13.45% over the next twelve months.
That rating is better than 79% of stocks based on data compiled by InvestorsObserver.
Click Here to get the full report on BIO-TECHNE Corp (TECH) Stock.
Why are Analyst Ratings Important?
Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected.
InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.
What's Happening With BIO-TECHNE Corp Stock Today?
BIO-TECHNE Corp (TECH) stock is down -0.19% while the S&P 500 has gained 0.6% as of 1:22 PM on Thursday, Dec 12. TECH is lower by -$0.40 from the previous closing price of $215.69 on volume of 54,630 shares. Over the past year the S&P 500 is higher by 19.22% while TECH has gained 32.91%. TECH earned $2.39 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 90.09.
